Actavis Inc (ACT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.7%. By the end of trading, Actavis rose $49.89 (58.2%) to $135.62 on light volume. Throughout the day, 758,121 shares of Actavis exchanged hands as compared to its average daily volume of 1,668,500 shares. The stock ranged in a price between $134.60-$137.12 after having opened the day at $136.48 as compared to the previous trading day's close of $85.73. Other companies within the Drugs industry that increased today were: Senesco Technologies ( SNTI), up 59.3%, Verenium Corporation ( VRNM), up 37.1%, Zalicus ( ZLCS), up 14.5% and GW Pharmaceuticals PLC ADR ( GWPH), up 13.6%.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $18.1 billion and is part of the health care sector. Shares are up 59.1% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 40.0%, Inovio Pharmaceuticals ( INO), down 13.3%, Opexa Therapeutics ( OPXA), down 10.6% and Alcobra ( ADHD), down 10.0% , were all laggards within the drugs industry with Amgen ( AMGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Trump to Blame for Oil's Recent Surge, Not OPEC

Trump to Blame for Oil's Recent Surge, Not OPEC

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await